Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'PHASE-II' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 5805 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Cohen, EEW; Vokes, EE
      Esophageal cancer therapy: A decade of inertia

      CANCER JOURNAL
    2. Wolff, RA
      Novel therapies for pancreatic cancer

      CANCER JOURNAL
    3. Argiris, A; Murren, JR
      Advances in chemotherapy for small cell lung cancer: Single-agent activityof newer agents

      CANCER JOURNAL
    4. Gitlitz, BJ; Hoffman, DMJ; Moldawer, N; Belldegrun, A; Figlin, RA
      Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: An analysis of 124 consecutively treated patients

      CANCER JOURNAL
    5. Aviles, A; Leon, MI; Diaz-Maqueo, JC; Garcia, EL; Cleto, S; Neri, N
      Rituximab in the treatment of refractory follicular lymphoma - Six doses are better than four

      JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH
    6. Singh, S; Cunningham, C; Buchanan, A; Jolly, DJ; Nemunaitis, J
      Toxicity assessment of intratumoral injection of the herpes simplex type Ithymidine kinase gene delivered by retrovirus in patients with refractory cancer

      MOLECULAR THERAPY
    7. Treon, SP; Agus, TB; Link, B; Rodrigues, G; Molina, A; Lacy, MQ; Fisher, DC; Emmanouilides, M; Richards, AI; Clark, B; Lucas, MS; Schlossman, R; Schenkein, D; Lin, B; Kimby, E; Anderson, KC; Byrd, JC
      CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia

      JOURNAL OF IMMUNOTHERAPY
    8. Steer, C; Harper, P
      Is there any place for cytotoxic chemotherapy in endometrial cancer?

      BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY
    9. Podczaski, E; Mortel, R
      Hormonal treatment of endometrial cancer: past, present and future

      BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY
    10. Miller, KD; Spooner, K; Herpin, BR; Rock-Kress, D; Metcalf, JA; Davey, RT; Falloon, J; Kovacs, JA; Polis, RA; Walker, RE; Masur, H; Lane, HC
      Immunotherapy of HIV-infected patients with intermittent interleukin-2: Effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion

      CLINICAL IMMUNOLOGY
    11. Stein, E
      Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    12. Marriott, JB; Muller, G; Stirling, D; Dalgleish, AG
      Immunotherapeutic and antitumour potential of thalidomide analogues

      EXPERT OPINION ON BIOLOGICAL THERAPY
    13. Zogakis, TG; Libutti, SK
      General aspects of anti-angiogenesis and cancer therapy

      EXPERT OPINION ON BIOLOGICAL THERAPY
    14. Preti, RA; Lazarus, HM; Winter, J; Stadtmauer, EA; Nadasi, S; McMannis, J; Karandish, S; Jennis, A; Goldberg, SL; Pecora, AL
      Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer

      CYTOTHERAPY
    15. Johnston, SRD; Kaye, S
      Caelyx: treatment for relapsing ovarian cancer

      HOSPITAL MEDICINE
    16. Trojan, A; Anagnostara, A; Fost, L
      Thalidomide: near complete regression of extramedullary bulk in refractorymultiple myeloma

      SWISS MEDICAL WEEKLY
    17. Bellott, R; Pouna, P; Robert, J
      Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome

      JOURNAL OF CHROMATOGRAPHY B
    18. Kong, ANT; Yu, R; Hebbar, V; Chen, C; Owuor, E; Hu, R; Ee, R; Mandlekar, S
      Signal transduction events elicited by cancer prevention compounds

      MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    19. Santana-Rios, G; Orner, GA; Amantana, A; Provost, C; Wu, SY; Dashwood, RH
      Potent antimutagenic activity of white tea in comparison with green tea inthe Salmonella assay

      MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
    20. Guyonnet, D; Belloir, C; Suschetet, M; Siess, MH; Le Bon, AM
      Antimutagenic activity of organosulfur compounds from Allium is associatedwith phase II enzyme induction

      MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
    21. Barry, OP; Kazanietz, MG
      Protein kinase C isozymes, novel phorbol ester receptors and cancer chemotherapy

      CURRENT PHARMACEUTICAL DESIGN
    22. Brandes, AA; Basso, U; Pasetto, LM; Ermani, M
      New strategy developments in brain tumor therapy

      CURRENT PHARMACEUTICAL DESIGN
    23. Jelic, S; Babovic, N; Stamatovic, L; Kreacic, M; Matkovic, S; Popov, I
      Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures - A single-center study

      MEDICAL ONCOLOGY
    24. Atkins, MB; Dutcher, J; Weiss, G; Margolin, K; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
      Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part I.IL-2-based clinical trials

      MEDICAL ONCOLOGY
    25. Dutcher, J; Atkins, MB; Margolin, K; Weiss, G; Clark, J; Sosman, J; Logan, T; Aronson, F; Mier, J
      Kidney cancer: The Cytokine Working Group experience (1986-2001) - Part II: Management of IL-2 toxicity and studies with other cytokines

      MEDICAL ONCOLOGY
    26. Pangalis, GA; Dimopoulou, MN; Angelopoulou, MK; Tsekouras, C; Vassilakopoulos, TP; Vaiopoulos, G; Siakantaris, MP
      Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders - A review

      MEDICAL ONCOLOGY
    27. Karapetis, CS; Yip, D; Virik, K; Strickland, A; Ryder, K; Cowling, M; Harper, PG
      Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil inthe treatment of carcinoma of unknown primary site

      MEDICAL ONCOLOGY
    28. Han, JY; Choi, BG; Song, DH; Ahn, JG; Yoon, JS; Lee, KS
      Vinorelbine-associated myelopathy in a patient who previously received paclitaxel - A case report

      MEDICAL ONCOLOGY
    29. Harries, M; Kaye, SB
      Recent advances in the treatment of epithelial ovarian cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    30. Fishman, M; Seigne, J; Antonia, S
      Novel therapies for renal cell carcinoma

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    31. Harrington, KJ
      Liposomal cancer chemotherapy: current clinical applications and future prospects

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    32. Wadler, S
      New developments in the treatment of ovarian cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    33. Harris, KA; Small, EJ
      Hormonal treatment for prostate cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    34. McKeage, MJ
      Lobaplatin: a new antitumour platinum drug

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    35. Tentori, L; Portarena, I; Bonmassar, E; Graziani, G
      Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells

      CELL DEATH AND DIFFERENTIATION
    36. Johnson, PWM
      The therapeutic use of antibodies for malignancy

      TRANSFUSION CLINIQUE ET BIOLOGIQUE
    37. Singhal, S; Mehta, J
      Thalidomide in cancer - Potential uses and limitations

      BIODRUGS
    38. Matheson, AJ; Nobel, S
      Management of colorectal cancer - Defining the role of raltitrexed

      DISEASE MANAGEMENT & HEALTH OUTCOMES
    39. Schuette, W; Bork, I; Wollschlager, B; Schadlich, S
      Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer

      CLINICAL DRUG INVESTIGATION
    40. Jennings, MT; Iyengar, S
      Pharmacotherapy of malignant astrocytomas of children and adults - Currentstrategies and future trends

      CNS DRUGS
    41. Brown, RE; Hutton, J; Burrell, A
      Cost effectiveness of treatment options in advanced breast cancer in the UK

      PHARMACOECONOMICS
    42. Plosker, GL; Hurst, M
      Paclitaxel - A pharmacoeconomic review of its use in non-small cell lung cancer

      PHARMACOECONOMICS
    43. Cuomo, AM; Della Cuna, FSR; Baiardi, P; Torazzo, R; Preti, P; Della Cuna, GR
      Three conventional-drug combination (ifosfamide, carboplatin, etoposide-ICE regimen) in advanced non-small cell lung cancer (NSCLC)

      JOURNAL OF CHEMOTHERAPY
    44. Tognoni, A; Pensa, F; Vaira, F; Vigani, A; Bancalari, L; Fiasella, L; Maggiani, R; Canessa, P; Pronzato, P
      A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer

      JOURNAL OF CHEMOTHERAPY
    45. Imam, SK
      Status of radioimmunotherapy in the new millennium

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    46. Aviles, A; Talavera, A; Diaz-Maqueo, JC; Garcia, E; Cleto, S; Neri, N
      Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma

      CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
    47. Friedberg, JW; Neuberg, D; Monson, J; Jallow, H; Nadler, LM; Freedman, AS
      The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma

      BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
    48. Peng, LS; Penichet, ML; Dela Cruz, JS; Sampogna, SL; Morrison, SL
      Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)

      JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
    49. Wood, AM
      Rituximab: An innovative therapy for non-Hodgkin's lymphoma

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    50. Millikan, R; Baez, L; Banerjee, T; Wade, J; Edwards, K; Winn, R; Smith, TL; Logothetis, C
      Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer

      UROLOGIC ONCOLOGY
    51. Vogelzang, NJ
      Medical oncology update

      UROLOGIC ONCOLOGY
    52. Baselga, J
      Is circulating HER-2 more than just a tumor marker?

      CLINICAL CANCER RESEARCH
    53. Buzaid, AC; Atkins, M
      Practical guidelines for the management of biochemotherapy-related toxicity in melanoma

      CLINICAL CANCER RESEARCH
    54. Shah, MA; Schwartz, GK
      Cell cycle-mediated drug resistance: An emerging concept in cancer therapy

      CLINICAL CANCER RESEARCH
    55. Shan, D; Gopal, AK; Press, OW
      Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells

      CLINICAL CANCER RESEARCH
    56. Jung, CP; Motwani, MV; Schwartz, GK
      Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotidereductase M2 subunit

      CLINICAL CANCER RESEARCH
    57. Robinson, BW; Shewach, DS
      Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breastcarcinoma cell lines

      CLINICAL CANCER RESEARCH
    58. Kruger, EA; Figg, WD
      Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex vivo rat aortic ring angiogenesis assay

      CLINICAL CANCER RESEARCH
    59. Maggiorella, L; Frascogna, V; Poullain, MG; Berlion, M; Lucas, C; Razy, SD; Eschwege, F; Bourhis, J
      The olivacine S16020 enhances the antitumor effect of ionizing radiation without increasing radio-induced mucositis

      CLINICAL CANCER RESEARCH
    60. Minotti, G; Saponiero, A; Licata, S; Menna, P; Calafiore, AM; Teodori, G; Gianni, L
      Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium

      CLINICAL CANCER RESEARCH
    61. Seraj, MJ; Thomas, AR; Chin, JL; Theodorescu, D
      Molecular determination of perivesical and lymph node metastasis after radical cystectomy for urothelial carcinoma of the bladder

      CLINICAL CANCER RESEARCH
    62. Kang, MH; Figg, WD; Ando, Y; Blagosklonny, MV; Liewehr, D; Fojo, T; Bates, SE
      The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel

      CLINICAL CANCER RESEARCH
    63. Birner, P; Oberhuber, G; Stani, J; Reithofer, C; Samonigg, H; Hausmaninger, H; Kubista, E; Kwasny, W; Kandioler-Eckersberger, D; Gnant, M; Jakesz, R
      Evaluation of the United States food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer

      CLINICAL CANCER RESEARCH
    64. Ino, Y; Betensky, RA; Zlatescu, MC; Sasaki, H; Macdonald, DR; Stemmer-Rachamimov, AO; Ramsay, DA; Cairncross, JG; Louis, DN
      Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis

      CLINICAL CANCER RESEARCH
    65. Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T
      Schedule dependency of antitumor activity in combination therapy with capecitabine/5 '-deoxy-5-fluorouridine and docetaxel in breast cancer models

      CLINICAL CANCER RESEARCH
    66. Doyle, TH; Mornex, F; McKenna, G
      The clinical implications of gemcitabine radiosensitization

      CLINICAL CANCER RESEARCH
    67. Takimoto, CH
      Why drugs fail: Of mice and men revisited

      CLINICAL CANCER RESEARCH
    68. Harrington, KJ; Mohammadtaghi, S; Uster, PS; Glass, D; Peters, AM; Vile, RG; Stewart, JSW
      Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes

      CLINICAL CANCER RESEARCH
    69. Kanzawa, F; Koizumi, F; Koh, Y; Nakamura, T; Tatsumi, Y; Fukumoto, H; Saijo, N; Yoshioka, T; Nishio, K
      In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction

      CLINICAL CANCER RESEARCH
    70. Ferguson, WS; Harris, MB; Goorin, AM; Gebhardt, MC; Link, MP; Shochat, SJ; Siegal, GP; Devidas, M; Grier, HE
      Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group trial

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    71. Weigel, BJ; Breitfeld, PP; Hawkins, D; Crist, WM; Baker, KS
      Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    72. Hurwitz, CA; Strauss, LC; Kepner, J; Kretschmar, C; Harris, MB; Friedman, H; Kun, L; Kadota, R
      Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    73. Raney, RB; Anderson, JR; Barr, FG; Donaldson, SS; Pappo, AS; Qualman, SJ; Wiener, ES; Maurer, HM; Crist, WM
      Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for intergroup rhabdomyosarcoma study V

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    74. Breitfeld, PP; Lyden, E; Raney, RB; Teot, LA; Wharam, M; Lobe, T; Crist, WM; Maurer, HM; Donaldson, SS; Ruymann, FB
      Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    75. Cairo, MS; Shen, V; Krailo, MD; Bauer, M; Miser, JS; Sato, JK; Blatt, J; Blazar, BR; Frierdich, S; Liu-Mares, W; Reaman, GH
      Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children withrecurrent or refractory solid tumors: A Children's Cancer Group report

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    76. Havrilesky, LJ; McMahon, CP; Lobenhofer, EK; Whitaker, R; Marks, JR; Berchuck, A
      Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones

      JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION
    77. Pirtskhalaishvili, G; Hrebinko, RL; Nelson, JB
      The treatment of prostate cancer - An overview of current options

      CANCER PRACTICE
    78. Smith, JA
      Alemtuzumab - A new option for refractory chronic lymphocytic leukemia?

      CANCER PRACTICE
    79. Kintzel, PE
      Prophylaxis for paclitaxel hypersensitivity reactions

      ANNALS OF PHARMACOTHERAPY
    80. DeHart, RM; Morehead, MS
      Mifepristone

      ANNALS OF PHARMACOTHERAPY
    81. Armstrong, WS; Kazanjian, P
      Use of cytokines in human immunodeficiency virus-infected patients: Colony-stimulating factors, erythropoietin, and interleukin-2

      CLINICAL INFECTIOUS DISEASES
    82. Lesser, GJ
      Chemotherapy of low-grade gliomas

      SEMINARS IN RADIATION ONCOLOGY
    83. Chang, S; Theodosopoulos, P; Sneed, P
      Multidisciplinary management of adult anaplastic astrocytomas

      SEMINARS IN RADIATION ONCOLOGY
    84. Vermorken, JB
      The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    85. Hansen, SW
      Gemcitabine in the treatment of ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    86. Conte, PF; Gadducci, A; Cianci, C
      Second-line treatment and consolidation therapies in advanced ovarian cancer

      INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
    87. Leong, SS; Tan, EH; Khoo-Tan, HS; Yang, TL; Wee, J; Tan, SH; Poh, WT; Tan, NG
      Recurrent nasopharyngeal carcinoma presenting as diffuse dermal lymphatic infiltration in the neck: Three case reports

      HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
    88. Niethammer, A; Gaedicke, G; Lode, HN; Wrasidlo, W
      Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumor activity and water solubility

      BIOCONJUGATE CHEMISTRY
    89. Harrison, D; Sauthoff, H; Heitner, S; Jagirdar, J; Rom, WN; Hay, JG
      Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved - Deletion of the viral E1b-19-kD gene increases the viral oncolytic effect

      HUMAN GENE THERAPY
    90. Cohen, BJ; Moskowitz, C; Straus, D; Noy, A; Hedrick, E; Zelenetz, A
      Phosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma

      LEUKEMIA & LYMPHOMA
    91. Takagi, T; Saotome, T
      Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    92. Chen, CL; Rawwas, J; Sorrell, A; Eddy, L; Uckun, FM
      Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients

      LEUKEMIA & LYMPHOMA
    93. Vidarsson, B; Abonour, R; Williams, EC; Woodson, RD; Turman, NJ; Kim, K; Mosher, DF; Wiersma, SR; Longo, WL
      Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia

      LEUKEMIA & LYMPHOMA
    94. Tinmouth, A; Zanke, B; Imrie, KR
      Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    95. Cartron, G; Voillat, L; Desablens, B; Le Maignan, C; Milpied, N; Foussard, C; Dugay, J; Maakaroun, A; De Muret, A; Colombat, P
      Continuous infusion of vincristine-doxorubicin with bolus of Dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    96. Gregory, SA; Vose, J; Modiano, M; Kraemer, K; Rifkin, R; Rubin, A; Menduni, T; Ghalie, R
      Mitoxantrone and fludarabine in the treatment of patients with non-Hodgkin's lymphoma failing primary therapy with a doxorubicin- or mitoxantrone-containing regimen

      LEUKEMIA & LYMPHOMA
    97. Wolff, AC
      Systemic therapy

      CURRENT OPINION IN ONCOLOGY
    98. Coiffier, B
      Diffuse large cell lymphoma

      CURRENT OPINION IN ONCOLOGY
    99. Leonard, JP; Schattner, EJ; Coleman, M
      Biology and management of mantle cell lymphoma

      CURRENT OPINION IN ONCOLOGY
    100. Godley, PA; Taylor, M
      Renal cell carcinoma

      CURRENT OPINION IN ONCOLOGY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/10/20 alle ore 12:03:37